Browsing publications by Dr David Sheridan

Newcastle AuthorsTitleYear
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Fiona Fenwick
Dr R Neely
et al.
Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial2014
Professor Margaret Bassendine
Dr David Sheridan
Jaime Jonsson
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection2013
Dr David Sheridan
Dr R Neely
Professor Margaret Bassendine
Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)2013
Professor Margaret Bassendine
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Dr R Neely
et al.
Lipids and HCV2013
Dr David Sheridan
Dr Daniel Felmlee
Dr Simon Bridge
Fiona Fenwick
Professor Geoff Toms
et al.
Metabolic Syndrome and Insulin Resistance are Associated with Maximum Hepatitis C Lipoviral Particles in Genotype 1 Infection2013
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Fiona Fenwick
Professor Margaret Bassendine
et al.
Omega-3 Fatty Acids and/or Fluvastatin in Hepatitis C Prior Non-Responders to Combination Anti-Viral Therapy - A Pilot Randomised Clinical Trial2013
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Professor Geoff Toms
Dr R Neely
et al.
Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity2012
Professor Margaret Bassendine
Dr David Sheridan
IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study2011
Dr Simon Bridge
Dr David Sheridan
Dr Daniel Felmlee
Professor Geoff Toms
Professor Margaret Bassendine
et al.
Apolipoprotein E and low-density, apolipoprotein B associated lipoviral particles in chronic Hepatitis C infection: Evidence for genotype-specific modulation of lipid pathways2011
Professor Margaret Bassendine
Dr David Sheridan
Dr Daniel Felmlee
Dr Simon Bridge
Professor Geoff Toms
et al.
HCV and the hepatic lipid pathway as a potential treatment target2011
123